Compare STZ & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STZ | GH |
|---|---|---|
| Founded | 1945 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Medical Specialities |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.6B | 20.6B |
| IPO Year | 1994 | 2018 |
| Metric | STZ | GH |
|---|---|---|
| Price | $132.52 | $157.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 19 |
| Target Price | ★ $175.63 | $119.79 |
| AVG Volume (30 Days) | 1.8M | ★ 2.2M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,139,000,000.00 | $982,021,000.00 |
| Revenue This Year | $0.73 | $33.30 |
| Revenue Next Year | $1.93 | $28.27 |
| P/E Ratio | $24.93 | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $126.45 | $51.44 |
| 52 Week High | $174.32 | $176.58 |
| Indicator | STZ | GH |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 59.32 |
| Support Level | $127.80 | $152.64 |
| Resistance Level | $135.09 | $174.08 |
| Average True Range (ATR) | 2.34 | 7.53 |
| MACD | 0.45 | 0.34 |
| Stochastic Oscillator | 56.17 | 56.24 |
Constellation Brands is the largest provider of alcoholic beverages across the beer, wine, and spirits categories in the US, generating more than 90% of revenue from Mexican beer imports under top-selling brands such as Modelo and Corona. The rest of the business includes some remaining wine and spirits brands, categories where the company has pruned assets in recent years. With its exclusive rights tied to the Mexican beer brands effective only in the US, the firm has limited revenue exposure to international markets. Constellation owns a 10% stake in Canopy Growth, a medicinal and recreational cannabis producer in Canada, and has a 50/50 joint venture with glass manufacturer Owens-Illinois in Mexico.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.